The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Open accessAbstract
BACKGROUND: Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event. METHODS: We randomly assigned patients with type 2 diabetes who had had a myocardial infarction or who had been hospitalized for unstable angina within the previous 180 days to receive lixisenatide or placebo in addition to locally determined standards of care. The trial was designed with adequate statistical power to assess whether lixisenatide was noninferior as well as superior to placebo, as defined by an upper boundary of the 95% confidence interval for the hazard ratio of less than 1.3 and 1.0, respectively, for the primary composite end point of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: The 6068 patients who underwent randomization were followed for a median of 25 months. A primary end-point event occurred in 406 patients (13.4%) in the lixisenatide group and in 399 (13.2%) in the placebo group (hazard ratio, 1.02; 95% confidence interval [CI], 0.89 to 1.17), which showed the noninferiority of lixisenatide to placebo (P<0.001) but did not show superiority (P=0.81). There were no significant between-group differences in the rate of hospitalization for heart failure (hazard ratio in the lixisenatide group, 0.96; 95% CI, 0.75 to 1.23) or the rate of death (hazard ratio, 0.94; 95% CI, 0.78 to 1.13). Lixisenatide was not associated with a higher rate of serious adverse events or severe hypoglycemia, pancreatitis, pancreatic neoplasms, or allergic reactions than was placebo. CONCLUSIONS: In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events. (Funded by Sanofi; ELIXA ClinicalTrials.gov number, NCT01147250.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“in the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial,14 the GLP-1–receptor agonist lixisenatide, which is shorter-acting than and structurally dissimilar to liraglutide, did not show any cardiovascular benefit in patients with diabetes and a recent acute coronary syndrome.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“No increased risk of heart failure hospitalization has been identified in the cardiovascular outcomes trials of the GLP-1 RAs lixisenatide, liraglutide, semaglutide, exenatide once weekly, albiglutide, or dulaglutide compared with placebo (261,264,265,296,297).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [297]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [641]
Experimental — accuracy not yet measuredIn the citing paper
“The study showed that lixisenatide is not inferior, although not superior, to placebo in cardiovascular safety.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [55]
In the citing paper
“The indication is to effectively reduce glycosylated hemoglobin levels in patients with T2DM by reducing fasting and postprandial blood glucose levels (61, 62).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [61]
In the citing paper
“In the ELIXA trial, lixisenatide 10 or 20 μg o.d. was non-inferior to placebo, but did not significantly affect a four-point MACE (three-point MACE plus hospitalization for unstable angina) in patients with T2DM post-ACS.158”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“Most GLP-1 RAs had a neutral effect on risk of HF hospitalization in the placebo-controlled RCTs assessing CV safety of glucose-lowering medications in patients with T2DM with or at high risk of ASCVD, despite increasing heart rate by 3-5 b.p.m. 70,72,158- 163,544”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide ER, dulaglutide, efpeglenatide) have a neutral effect on the risk of HF hospitalization, and should be considered for glucose-lowering treatment in patients with T2DM at risk of or with HF. 70,158-164,545 IIa A”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) was the first to report and showed that the short-acting GLP-1 receptor agonist lixisenatide had no impact on MACEs in 6068 patients after an acute coronary syndrome.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [224]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“No increased risk of heart failure hospitalization has been identi fi ed in the cardiovascular outcomes trials of the GLP-1 receptor agonists lixisenatide, liraglutide, semaglutide, exenatide once-weekly, albiglutide, or dulaglutide compared with placebo ( Table 10.3 B ) (203,204,207 -209).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“However, two GLP-1 analogues tested in two studies demonstrated no advantage in influencing cardiovascular outcome.278,279”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [279]
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [23]
In the citing paper
“In these trials, GLP-1 receptor agonists had a neutral effect on the risk for HF hospitalization.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,016
Trujillo, J. M., & Goldman, J. D. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1962 · Cited by 21
Umpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 22
Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure
Verbrugge, F. H. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0340-1 · Cited by 22
dʼEmden, M. C., Amerena, J. V., Deed, G., Pollock, C. A., & Cooper, M. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.023 · Cited by 22
Nova abordagem para o tratamento da diabetes: da glicemia à doença cardiovascular
Aguíar, C., Duarte, R., & Carvalho, D. M. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2018.03.013 · Cited by 22
Alfayez, O. M., Almutairi, A. R., Aldosari, A. A., & Yami, M. S. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.04.003 · Cited by 21
Ramos, A. M., Fernández‐Fernández, B., Pérez-Gómez, M. V., Julio, S. M. C., Sánchez-Niño, M. D., Sanz, A. B., Ruiz‐Ortega, M., & Ortíz, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1690450 · Cited by 23
Antidiabetic drugs and blood pressure changes
Ilias, Ι., Thomopoulos, C., Michalopoulou, H., Bazoukis, G., Tsioufis, C. P., & Makris, T. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105108 · Cited by 22
Dermatitis due to Olindias sambaquiensis: a case report.
Kokelj, F., Mianzán, H., Avian, M., & Burnett, J. W. (1993) · PubMed · Cited by 22
Liu, T., Fan, Z., Li, Y., Xiao, B., & Chang, H. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133229 · Cited by 23
Singh, A. K., & Singh, R. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1287562 · Cited by 21
Hurren, K. M., & Dunham, M. W. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494727 · Cited by 20
Górriz, J. L., Romera, I., Cobo, A., O’Brien, P. D., & Merino-Torres, J. F. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01198-5 · Cited by 25
Ali, M. U., Mancini, G. B. J., Fitzpatrick‐Lewis, D., Lewis, R., Jovkovic, M., Zieroth, S. R., O’Meara, E., Connelly, K. A., & Sherifali, D. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.05.011 · Cited by 21
Lopez, P. D., Bhatia, K., Bohra, C., Mahmood, K., Baruch, L., & Eng, C. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.07.012 · Cited by 24
Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
Yazıcı, D., Eser, H. Y., Kiyici, S. K., Sancak, S., Sezer, H., Uygur, M., & Yumuk, V. (2022) · Obesity Facts · doi:10.1159/000526808 · Cited by 26
Skeik, N., Elejla, S. A., Sethi, A., Manunga, J. M., & Mirza, A. K. (2023) · Vascular Medicine · doi:10.1177/1358863x221143811 · Cited by 21
Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice
Hsuan, C., Teng, S. I. F., Hsu, C., Liao, D., Chang, A. J.-W., Lee, H.-L., Hee, S., Chang, Y., & Chuang, L. (2023) · Biomedicines · doi:10.3390/biomedicines11030662 · Cited by 23
Semaglutide-eye-catching results
Berković, M. C., & Strollo, F. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i4.424 · Cited by 21
Cardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 21
Rodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 21
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
Chatzianagnostou, K., Gaggini, M., Suman, A. F., Simonini, L., & Vassalle, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116218 · Cited by 20
Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. E. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.05 · Cited by 23
Novel antidiabetic drugs and cardiovascular risk: Primum non nocere
Bonadonna, R. C., Borghi, C., Consoli, A., & Volpe, M. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.05.007 · Cited by 21
Ji, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 21
Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors
Bistola, V., Lambadiari, V., Dimitriadis, G., Ioannidis, I., Makrilakis, K., Tentolouris, N., Τσάπας, Α., & Parissis, J. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9674-3 · Cited by 21
Unexplained reciprocal regulation of diabetes and lipoproteins
Higuchi, S., Izquierdo, M. C., & Haeusler, R. A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000521 · Cited by 20
Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure
Weir, D. L., Abrahamowicz, M., Beauchamp, M., & Eurich, D. T. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13448 · Cited by 21
Hinton, W., Feher, M. D., Munro, N. M., Walker, M., & de Lusignan, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13710 · Cited by 19
Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
Hinnen, D. A., & Kruger, D. F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188705 · Cited by 23
Lăcătușu, C.-M., Grigorescu, E.-D., Stătescu, C., Sascău, R. A., Onofriescu, A., & Mihai, B. M. (2019) · Medicina · doi:10.3390/medicina55090592 · Cited by 23
Lajara, R. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1670017 · Cited by 21
Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.
Leon, N., LaCoursiere, R. J., Yarosh, D., & Patel, R. S. (2017) · PubMed Central · Cited by 21
Nassif, M. E., & Kosiborod, M. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.025 · Cited by 20
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update – The User’s Guide
Senior, P. A., Houlden, R. L., Kim, J., MacKay, D., Nagpal, S., Rabi, D. M., Sherifali, D., & BAJAJ, H. S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.002 · Cited by 23
Araki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., Ishii, H., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0865 · Cited by 24
Liraglutide for treating type 1 diabetes
Dejgaard, T. F., Frandsen, C. S., Holst, J. J., & Madsbad, S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1160050 · Cited by 21
Samidurai, A., Salloum, F. N., Durrant, D., Chernova, O. B., Kukreja, R. C., & Das, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14059 · Cited by 21
An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 23
Milligan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.010 · Cited by 20
Schernthaner, G., Cahn, A., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dcs15-3009 · Cited by 20
Hunt, B., Vega-Hernandez, G., Valentine, W. J., & Kragh, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12890 · Cited by 20
Schütt, K. S., & Marx, N. (2017) · Herz · doi:10.1007/s00059-017-4558-1 · Cited by 20
Wolsk, E., Claggett, B. L., Díaz, R., Dickstein, K., Gerstein, H. C., Køber, L., Lawson, F. C., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029503 · Cited by 20
Self-citationChou, C., Chang, Y., Yang, J.-L., Wang, J., Lee, T.-E., Wang, R., & Hung, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16101-1 · Cited by 20
Emerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 22
Recent achievements and future directions of anti-obesity medications
Grandl, G., Novikoff, A., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101100 · Cited by 23
Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
Rydén, L., Shahim, B., & Mellbin, L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.035 · Cited by 20
The EMPA-REG outcome study: critical appraisal and potential clinical implications
Perseghin, G., & Solini, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0403-8 · Cited by 20
Diabetes Research and Care Through the Ages
Zinman, B., Skyler, J. S., Riddle, M. C., & Ferrannini, E. (2017) · Diabetes Care · doi:10.2337/dci17-0042 · Cited by 21
Self-citationEffects of incretin-based therapies on renal function
Tsimihodimos, V., & Elisaf, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.049 · Cited by 21
Effects of Diabetes Medications Targeting the Incretin System on the Kidney
MacIsaac, R. J., & Thomas, M. C. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10380917 · Cited by 19
Kim, G. S., Park, J. H., & Won, J. C. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.2.106 · Cited by 20
Farngren, J., & Åhrén, B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.016 · Cited by 20
Nicolucci, A., Candido, R., Cucinotta, D., Graziano, G., Rocca, A., Rossi, M. C., Tuccinardi, F., & Manicardi, V. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01043-z · Cited by 20
Petrie (2016) · doi:10.1097/hjh.0000000000000890 · Cited by 20
Perkins, B. A., Udell, J. A., & Cherney, D. Z. I. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.03.410 · Cited by 20
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 21
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 24
Gitto, M., Catapano, F., Francone, M., Mincione, G., Scialò, V., Pivato, C. A., Lisi, C., Regazzoli, D., Cao, D., Fiorina, R. M., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02606-z · Cited by 21
Luconi, M., Raimondi, L., Franco, A. D., & Mannucci, E. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.09.001 · Cited by 19
Mezquita‐Raya, P., de Arellano, A. R., Kragh, N., Vega-Hernandez, G., Pöhlmann, J., Valentine, W. J., & Hunt, B. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0239-6 · Cited by 18
Kant, R., Munir, K. M., Kaur, A., & Verma, V. K. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i6.324 · Cited by 19
Kameda, T., Kumamaru, H., Nishimura, S., Kohsaka, S., & Miyata, H. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1729710 · Cited by 19
Pulipati, V. P., Ravi, V., & Pulipati, P. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320903638 · Cited by 19
Hulst, A., Visscher, M., Cherpanath, T., van de Wouw, L., Godfried, M., Thiel, B., Gerritse, B., Scohy, T., Bouwman, R. A., Willemsen, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030673 · Cited by 21
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Lo, C. W. H., Fei, Y., & Cheung, B. M. Y. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.19 · Cited by 20
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2020
Orozco‐Beltrán, D., Cuixart, C. B., Sánchez, J. J. A., Banegas, J. R., Cuenca, A. M. C., Gil-Guillén, V. F., Rioboó, E. M., & Pérez, J. N. (2020) · Atención Primaria · doi:10.1016/j.aprim.2020.08.002 · Cited by 24
Diabetes Management in Patients with Heart Failure
Shen, J., & Greenberg, B. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0296 · Cited by 21
Rosselló, X., Ferreira, J. P., Caimari, F., Lamiral, Z., Sharma, A., Mehta, C. R., Bakris, G. L., Cannon, C. P., White, W. B., & Zannad, F. M. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01859-2 · Cited by 20
Bhailis, A. M. D., Azmi, S., & Kalra, P. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211020664 · Cited by 18
Donate‐Correa, J., Sánchez-Niño, M. D., González-Luis, A., Ferri, C. M., Martín-Olivera, A., Martín‐Núñez, E., Fernández‐Fernández, B., Tagua, V. G., Fernández, C. M., Ortíz, A., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac143 · Cited by 19
Ngoc, N. B., Nguyen, L., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15009 · Cited by 21
Semaglutide and Other GLP-1 Agonists: A Boon for the Arthroplasty Industry?
Magruder, M. L., Jacofsky, D., Springer, B. D., Scuderi, G. R., Hameed, D., & Mont, M. A. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.12.014 · Cited by 19
Nauck, M. A., Meier, J. J., & Schmidt, W. E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12981 · Cited by 19
Jorsal, A., Wiggers, H., & McMurray, J. J. V. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.007 · Cited by 20
Self-citationOrthodontic Treatment Consideration in Diabetic Patients
Almadih, A., Al-Zayer, M., Dabel, S., Alkhalaf, A. H., Mayyad, A. A., Bardisi, W., Alshammari, S. B., & Alsihati, Z. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3285w · Cited by 19
Wijkman, M. O., Dena, M., Dahlqvist, S., Sofizadeh, S., Hirsch, I. B., Tuomilehto, J. O., Mårtensson, J., Torffvit, O., Imberg, H., Saeed, A., et al. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13447 · Cited by 18
Diabetes Care Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care
Riddle, M. C., Blonde, L., Gerstein, H. C., Gregg, E. W., Holman, R. R., Lachin, J. M., Nichols, G. A., Turchin, A., & Cefalu, W. T. (2019) · Diabetes Care · doi:10.2337/dci19-0020 · Cited by 21
Self-citationSGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
Schernthaner, G., Drexel, H., Moshkovich, E., Žilaitienė, B., Martinka, E., Czupryniak, L., Várkonyi, T. T., Janež, A., Ducena, K., Lalic, K. S., et al. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0387-y · Cited by 21
Shao, H., Yang, S., Stoecker, C., Fonseca, V. A., Hong, D., & Shi, L. (2019) · Value in Health · doi:10.1016/j.jval.2019.08.007 · Cited by 19
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 19
Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy
Butler, J., Januzzi, J. L., & Rosenstock, J. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14042 · Cited by 19
Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs
Lunder, M., Janić, M., & Šabović, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062796 · Cited by 20
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 19
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
Scheen, A. J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.009 · Cited by 18
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18
Jiao, X., Peng, P., Zhang, Q., & Shen, Y. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01319-x · Cited by 23
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Raza, F. A., Altaf, R., Bashir, T., Asghar, F., Altaf, R., Tousif, S., Goyal, A., Mohammed, A., Mohammad, M. F., Anan, M., et al. (2024) · Medicine · doi:10.1097/md.0000000000040364 · Cited by 27
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 18
Aristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Trujillo, D. A. V., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1605746 · Cited by 24
Niessner, A., Tamargo, J. L., Koller, L., Saely, C. H., Schmidt, T. A., Savarese, G., Waßmann, S., Rosano, G. M. C., Ceconi, C., Torp-Pedersen, C. T., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx625 · Cited by 18
Longato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa081 · Cited by 19
Energy metabolism homeostasis in cardiovascular diseases.
Wang, L.-Y., & Chen, C. (2021) · PubMed Central · doi:10.11909/j.issn.1671-5411.2021.12.006 · Cited by 18
Monteiro, P. F., Aguíar, C., Matos, P. L. P., Silva‐Nunes, J., Birne, R., Branco, P. Q., Calado, J., Melo, M., & Polónia, J. J. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.02.015 · Cited by 18
Recent advances in the treatment of patients with obesity and chronic kidney disease
Wahab, R. A., COHEN, R. V., & le Roux, C. W. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2203517 · Cited by 22
Krishnan, A., Hadi, Y. B., Hutson, W. R., Thakkar, S. J., & Singh, S. P. (2022) · Pancreas · doi:10.1097/mpa.0000000000002197 · Cited by 18
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
Wroge, J., & Williams, N. T. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016663218 · Cited by 17
Metadata
- Authors
- Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., Probstfield, J. L., Riddle, M. C., Solomon, S. D., & Tardif, J.-C.
- Affiliations
- Brigham and Women's Hospital (US)
- Stavanger University Hospital (NO)
- McMaster University (CA)
- Copenhagen University Hospital (DK)
- Sanofi (United States) (US)
- University of Zurich (CH)
- University of Washington Medical Center (US)
- Oregon Health & Science University (US)
- Montreal Heart Institute (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-03
- Volume
- 373
- Issue
- 23
- Pages
- 2247-2257
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2282578582
- Cited by
- 2,409
- References
- 38
- Citations by year
- 2026: 136 · 2025: 175 · 2024: 182 · 2023: 165 · 2022: 191 · 2021: 250 · 2020: 281 · 2019: 251 · 2018: 290 · 2017: 278 · 2016: 202 · 2015: 4
- FWCI
- 224.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- lixisenatide, type 2 diabetes, acute coronary syndrome, myocardial infarction, unstable angina, GLP-1 receptor agonists, cardiovascular outcomes, non-inferiority, major adverse cardiovascular events, heart failure hospitalization, serious adverse events, hypoglycemia, pancreatitis, pancreatic neoplasms, allergic reactions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Peptides, Proportional Hazards Models, Treatment Failure, Kaplan-Meier Estimate, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
